Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026

Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026

Same author

Narsoplimab: First Approval.

Drugs·2026

Same author

Aficamten: First Approval.

Drugs·2026

Same author

Elamipretide: First Approval.

Drugs·2025

Same author

Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms.

Drugs·2025

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Olaratumab: First Global Approval.

¹Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

|December 21, 2016

Summary

This summary is machine-generated.

Olaratumab, a novel antibody targeting platelet-derived growth factor receptor alpha (PDGFRα), has gained FDA approval for treating soft tissue sarcoma. This milestone marks a significant advancement in cancer therapy.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Related Experiment Videos

Last Updated: Mar 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Platelet-derived growth factor receptor alpha (PDGFRα) is a therapeutic target in various cancers.
Olaratumab is a fully human monoclonal antibody targeting PDGFRα.
Olaratumab inhibits downstream signaling by blocking PDGF ligand binding to PDGFRα.

Purpose of the Study:

To summarize the development of olaratumab.
To highlight key milestones leading to its first approval.
To detail its use in treating adult soft tissue sarcoma.

Main Methods:

Development of a fully human IgG1 monoclonal antibody.
Targeting of human platelet-derived growth factor receptor alpha (PDGFRα).
Phase II and III clinical trials in soft tissue sarcoma and other cancers.

Main Results:

Olaratumab received US FDA accelerated approval in October 2016 for soft tissue sarcoma in combination with doxorubicin.
Conditional approval was granted by the EMA in November 2016.
A confirmatory Phase III trial (ANNOUNCE) is ongoing.

Conclusions:

Olaratumab represents a significant development in targeted cancer therapy.
Its approval for soft tissue sarcoma offers a new treatment option for adult patients.
Further investigation in other cancers is ongoing.